We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luminex Hurt By Segmental Sluggishness, Stiff Competition
Read MoreHide Full Article
On Feb 20, we issued an updated research report on Luminex Corporation . A weak fourth quarter and stiff competition in the Medtech space currently plague the company.
The stock currently carries a Zacks Rank #4 (Sell).
What’s Deterring the Stock?
Luminex saw some sluggishness in the recently-reported fourth quarter of 2018.
Earnings per share in the fourth quarter dropped on a year-over-year basis. Per management, the departure of LabCorp impacted results.
Additionally, Luminex’s assay and molecular diagnostic revenues declined year over year in the quarter, impacted by LabCorp. Notably, assay revenues fell 11.7%, while molecular diagnostic revenues declined 11% year over year.
Moreover, Luminex’s Other segment saw a revenue decline of 14% year over year in the quarter.
In addition to this, Luminex operates in the highly competitive life sciences industry. The industry is characterized by rapid and continuous technological innovation. Currently, it is facing significant competitive headwinds in the respiratory market.
The company’s dependence on its partners for revenue generation may add to the woes. Luminex’s customers include clinical diagnostic, pharmaceutical, biotechnological, chemical and industrial companies. Reduced spending on research and diagnostics by these companies is likely to dent demand for Luminex’s products.
Price Performance
Despite the hurdles, shares of Luminex have rallied 28.1% compared with the industry’s 10.1% gain over the past year. The current level also compares favorably with the S&P 500 index’s 3% rally.
Penumbra’s long-term earnings growth rate is expected at 20%.
Wright Medical’s long-term earnings growth rate is expected at 11%.
DexCom’s next-quarter earnings per share are projected to grow 56.3%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Luminex Hurt By Segmental Sluggishness, Stiff Competition
On Feb 20, we issued an updated research report on Luminex Corporation . A weak fourth quarter and stiff competition in the Medtech space currently plague the company.
The stock currently carries a Zacks Rank #4 (Sell).
What’s Deterring the Stock?
Luminex saw some sluggishness in the recently-reported fourth quarter of 2018.
Earnings per share in the fourth quarter dropped on a year-over-year basis. Per management, the departure of LabCorp impacted results.
Additionally, Luminex’s assay and molecular diagnostic revenues declined year over year in the quarter, impacted by LabCorp. Notably, assay revenues fell 11.7%, while molecular diagnostic revenues declined 11% year over year.
Moreover, Luminex’s Other segment saw a revenue decline of 14% year over year in the quarter.
In addition to this, Luminex operates in the highly competitive life sciences industry. The industry is characterized by rapid and continuous technological innovation. Currently, it is facing significant competitive headwinds in the respiratory market.
The company’s dependence on its partners for revenue generation may add to the woes. Luminex’s customers include clinical diagnostic, pharmaceutical, biotechnological, chemical and industrial companies. Reduced spending on research and diagnostics by these companies is likely to dent demand for Luminex’s products.
Price Performance
Despite the hurdles, shares of Luminex have rallied 28.1% compared with the industry’s 10.1% gain over the past year. The current level also compares favorably with the S&P 500 index’s 3% rally.
Key Picks
Some better-ranked stocks in the broader medical space are Penumbra, Inc. (PEN - Free Report) , Wright Medical Group N.V. and DexCom. Inc. (DXCM - Free Report) . Notably, each of these stocks currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Penumbra’s long-term earnings growth rate is expected at 20%.
Wright Medical’s long-term earnings growth rate is expected at 11%.
DexCom’s next-quarter earnings per share are projected to grow 56.3%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>